CAPLYTA 21 MG CAPSULE
FDA nonproprietary name: lumateperone
For 30 capsules
Pharmacies pay
$1,716.01 filed
30 × $57.2004 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$1,682.95 filed
30 × $56.09832 per EA, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
0.98× estimated
Medicare paid about what pharmacies pay.
Part D averages every strength and form sold under “Caplyta” / “Lumateperone Tosylate” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$1,978.41 estimated
$1,716.01 + $257.40 (15%) + $5.00 fee per fill = $1,978.41
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
CAPLYTA 21 MG CAPSULE is how the CMS NADAC file names this product. The FDA NDC Directory lists it as lumateperone, under the trade name “CAPLYTA”.
FDA gives its dosage form as capsule and its route as oral.
The labeler, the company named on the label, is Intra-Cellular Therapies, Inc.
FDA’s Established Pharmacologic Class for it is Atypical Antipsychotic.
The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 72060-0121-40.
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $1,716.01 for 30 capsules (30 × $57.2004 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.
What NADAC measures · Why 30 capsules · NADAC explanation codes
The NDC
- 72060-0121-40 · Intra-Cellular Therapies, Inc · $57.2004 per EA · eff. 2026-09-23 filed
Other strengths, forms and brands
2 other products in the NADAC file share the FDA nonproprietary name lumateperone with CAPLYTA 21 MG CAPSULE.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| CAPLYTA 10.5 MG CAPSULE | $57.24296 per EA filed | $56.09832 per EA filed |
| CAPLYTA 21 MG CAPSULE this page | $57.2004 per EA filed | $56.09832 per EA filed |
| CAPLYTA 42 MG CAPSULE | $57.24714 per EA filed | $56.09832 per EA filed |
Part D is one average per brand and generic name, over every strength and form.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
Compared with its class
Its NADAC price is $57.2004 per EA filed.
Of the 130 other products in FDA’s Atypical Antipsychotic class priced per EA, 6 have a higher middle NADAC price and 124 a lower one. The one in the middle is OLANZAPINE-FLUOXETINE 6-25 MG, at $4.05968 per EA filed (eff. 2026-09-23).
Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What Medicare paid
Medicare Part D paid $1,682.95 for 30 capsules, at an average of $56.09832 per EA in 2024 (2024-01-01 to 2024-12-31) for “Caplyta” and “Lumateperone Tosylate”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 159,224 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 30 capsules? Is it lower than what I would pay through my insurance?
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for CAPLYTA 21 MG CAPSULE labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Caplyta / Lumateperone Tosylate: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.
Related pages
Its pharmacologic class
Related in the same class
- QUETIAPINE 150 MG TABLET
- ARIPIPRAZOLE 10 MG TABLET
- OLANZAPINE 10 MG TABLET
- RISPERIDONE 0.25 MG TABLET
- CLOZAPINE 100 MG TABLET